Search Results - david+neville

5 Results

Sort By:

Stable, High-Yield Production of DT390-EGF Fusion Protein for Treatment of EGF-Receptor-Positive Cancers

This invention relates to the stable and high-yield production of a high-potency toxin protein called DT390-EGF. This toxin was developed for the treatment of EGF-receptor-positive cancers, including bladder cancer. Initial methods for synthesizing DT390-EGF relied on the use of E. coli. However, the production in E. coli was difficult to prepare and...

Published: 7/25/2024 | Inventor(s): Jung-hee Woo, David Neville, Arthur Frankel, Andrew Thorburn, Michael Glode, Thomas Flaig

Keywords(s): cancers, DT390-EGF, EGF, Fusion, POSITIVE, Protein, RECEPTOR, treatment, VCXXXX, WKXXXX, XEXXXX

Category(s): TherapeuticArea > Oncology, Application > Therapeutics

A Fold-Back Diabody Format for Diphtheria Toxin-Based Immunotoxins That Can Increase Binding and Potency

NIH inventors, in collaboration with Scott and White Memorial Hospital inventors, have developed new immunotoxins comprising a mutant diphtheria toxin linked to an anti-prostate specific membrane antigen (PSMA) fold-back diabody. The fold-back diabody construct has a shortened linker region between the heavy and light chains of the antibody variable...

Published: 7/25/2024 | Inventor(s): David Neville

Keywords(s): A-dmDT390scfbDb591, Anti-prostratic, APPLICATION, Based, BINDING, CANCER, CB1AXX, CB1BXX, CB1CXX, CB1XXX, CBXXXX, CXXXXX, Diabody, DIPHTHERIA, Diptheria, Fold-back, FORMAT, Immunotoxin, IMMUNOTOXINS, INCREASE, particular, Potentcy, That, toxin

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Oncology, TherapeuticArea > Immunology, Application > Therapeutics

Methods of Inducing Immune Tolerance Using Immunotoxins

The invention concerns immunotoxins and methods of using the immunotoxins for the treatment of rejection response in a patient, including graft-versus-host disease and transplantation of organs, tissues and cells into a host. In a specific embodiment of the invention, the transplant involves pancreatic islet cells. The immunotoxins are targeted via...

Published: 7/25/2024 | Inventor(s): David Neville

Keywords(s): Activity, Agents, CB1XXX, CBXXXX, Cell, COMBINED, CXXXXX, Dendritic, Graft versus host disease, IB3XXX, IBXXXX, IMMUNE, Immunotoxin, IMMUNOTOXINS, Induce, INDUCING, INHIBIT, IN-VIVO, ISLET, IXXXXX, Maturation, Methds, Method, Methods, Novel, Pancreatic, RELATED, SUPPRESSANT, T, That, TOLERANCE, TRANSPLANTATION

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Immunology, Application > Research Materials, Application > Diagnostics, TherapeuticArea > Oncology, Application > Therapeutics

Methods for Expression and Purification of Immunotoxins

The invention concerns immunotoxins and methods of making the immunotoxins. Targeting of the immunotoxins occurs via an antibody that is specific to T cells. This allows the specific ablation of malignant T cells and resting T cells. The transient ablation of resting T cells can "reset" the immune system by accentuating tolerizing responses. As...

Published: 7/25/2024 | Inventor(s): David Neville

Keywords(s): Aplastic anemia, Are, Bivalent, CB6XXX, CBXXXX, COMPLEX, CXXXXX, ESSENTIAL, Graft versus host disease, IB3XXX, IBXXXX, Immunotoxin, IXXXXX, LOW, lymphoma, Media, PASTORIS, PICHIA, production, temperature

Category(s): Collaboration Sought > Licensing, Application > Research Materials, TherapeuticArea > Immunology, Application > Diagnostics, Application > Therapeutics, TherapeuticArea > Oncology

Immunotoxin with in-vivo T cell Suppressant Activity

The invention concerns immunotoxins and methods of using the immunotoxins for the treatment of autoimmune diseases and T cell malignancies. The immunotoxins are targeted via an antibody that is specific to T cells. This allows the specific ablation of malignant T cells and resting T cells. The transient ablation of resting T cells can "reset" the...

Published: 7/25/2024 | Inventor(s): David Neville

Keywords(s): Activity, Aplastic anemia, CB1XXX, CBXXXX, Cell, CXXXXX, IB3XXX, IBXXXX, IMMUNE, Immunotoxin, IMMUNOTOXINS, INDUCING, IN-VIVO, IXXXXX, lymphoma, Methods, Novel, SUPPRESSANT, T, TOLERANCE, UAXXXX, Vivo

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Oncology, TherapeuticArea > Immunology, TherapeuticArea > Rare / Neglected Diseases, Application > Diagnostics, Application > Research Materials, Application > Therapeutics